Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma Authors: Aaron R. Hansen, Carlos A. Gomez-Roca, Debbie G. J. Robbrecht, Loic Verlingue, Antoine Italiano, Julie E. Bauman, Neeltje Steeghs, Hans Prenen, Jérôme Fayette, James Spicer, Jiaxin Niu, Christin Habigt, Meike Schneider, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Daniela Schmid, Christophe Boetsch, Jehad Charo, Anton Kraxner, Volker Teichgräber, Nino Keshelava, Marcelo R. Bonomi Published: 2024 ABSTRACT AbstractPurpose:This phase Ib trial evaluated fibroblast activation protein-α–targeted IL2 variant (FAP-IL2v), a novel immunocytokine engineered to minimize CD25-mediated toxicities, in combination with cetuximab, in patients with recurrent, unresectable, or metastatic head and neck squamous cell carcinoma (HNSCC).Patients and Methods:Patients received FAP-IL2v either on a continuous weekly (QW) schedule or QW for 4 weeks and then every 2 weeks (Q2W). Cetuximab was dosed at QW or Q2W schedules. The primary objectives were to evaluate the safety and tolerability, maximum tolerated dose, pharmacokinetics, and clinical activity for the combination of FAP-IL2v with cetuximab. Exploratory objectives included pharmacodynamic analyses.Results:A total of 58 patients were enrolled, 19 patients into the dose-escalation part, and 39 patients into the expansion part. The maximum tolerated dose of FAP-IL2v was defined as 10 mg (QW/Q2W) in combination with cetuximab (500 mg/m2, Q2W), which was further tested in the expansion part. The most common FAP-IL2v–related adverse events with a grade 3 or 4 severity were hypophosphatemia (19%), lymphopenia (16%), and infusion-related reaction (14%). The pharmacokinetics of FAP-IL2v in combination with cetuximab was similar to that after administration as monotherapy. Consistent with the proposed mode of action, FAP-IL2v preferentially expanded intratumoral NK and CD8 T cells. Four patients achieved a partial response, and the objective response rate was 7% (95% confidence interval, 3.2–14.7).Conclusions:The safety profile of FAP-IL2v in combination with cetuximab was acceptable, and pharmacodynamic markers support the proposed mode of action of this combination, but the overall low antitumor activity does not warrant further clinical exploration in HNSCC. [Part C of Study BP29842 (NCT02627274).] Translational Relevance Simlukafusp alfa [fibroblast activation protein-α–targeted IL2v variant (FAP-IL2v) with abolished CD25 binding] is a novel immunocytokine developed to overcome the limitations of wildtype IL2 by selectively promoting immune responses in the microenvironment of tumors that overexpress FAP, while minimizing known side effects by abrogating CD25 binding. FAP-IL2v may augment antibody-dependent cellular cytotoxicity activity by activation and expansion of NK cells and may therefore serve as a versatile combination partner for the antibody-dependent cellular cytotoxicity–competent compound cetuximab. This phase Ib study explored the combination of FAP-IL2v and cetuximab in patients with recurrent, unresectable, or metastatic head and neck squamous cell carcinoma. The safety profile of the combination treatment was acceptable; however, the observed biological effect on NK cells did not translate into meaningful antitumor activity of the investigated treatment combination in this mostly checkpoint inhibitor–experienced patient population. Introduction Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is difficult to treat and associated with median survival of 15 months (1). The EGFR inhibitor cetuximab is standard of care in patients with locally advanced or recurrent and metastatic HNSCC (2). The PD-1 inhibitor pembrolizumab has replaced the EXTREME regimen of cetuximab and platinum-based doublet. There is currently no established standard of care for patients in subsequent lines of therapy; salvage cytotoxic chemotherapies (platinum, taxanes, and methotrexate if not previously given) and cetuximab are the limited options available. The exploration of IL2 as a monotherapy in HNSCC showed mixed results in clinical studies (3) and was not pursued further. Fibroblast activation protein–targeted IL2 variant (FAP-IL2v, also referred to as simlukafusp alfa or RO6874281) is a novel, monomeric, immunocytokine designed to overcome the limitations of wildtype IL2 by selectively promoting immune responses in the tumor microenvironment (4). FAP-IL2v consists of a single IL2v moiety with abolished CD25 binding capacity, fused with a human IgG1 antibody directed against FAP, a type II transmembrane glycoprotein with proteolytic activity (4). FAP is rarely expressed in healthy tissue but is involved in tissue remodeling processes and has been shown to be highly expressed on the surface of cancer-associated fibroblasts in the stroma of more than 90% of human epithelial tumors (5, 6). Due to activation of CD8+ T cells and NK cells, FAP-IL2v significantly enhanced the activity of several therapeutic antibodies in preclinical models, including those that mediate antibody-dependent cellular cytotoxicity (ADCC) via Fcɣ-R engagement (4). This phase Ib study (BP29842 part C) explored whether FAP-IL2v may augment ADCC activity of cetuximab through NK cell activation and expansion in patients with recurrent, unresectable, or metastatic HNSCC. FAP-IL2v monotherapy dose-finding was explored in part A of the study in various solid tumors (7) and preceded the exploration of this combination in part C. Patients and Methods Study design and objectives BP29842 part C (NCT02627274) was a first-in-human, open-label, multicenter phase Ib study evaluating FAP-IL2v in combination with cetuximab in a dose-escalation and expansion cohort. The primary objective of dose escalation was to evaluate the safety/tolerability, the pharmacokinetics (PK), and the maximum tolerated dose (MTD) and/or the optimal biological dose and/or the recommended dose for the combination in patients with recurrent, unresectable, or metastatic HNSCC. Primary objectives of the expansion included safety, PK, and therapeutic activity. Secondary objectives of both study segments included treatment-induced pharmacodynamic effects and preliminary antitumor activity. The study was conducted in accordance with the Declaration of Helsinki and ICH Good Clinical Practice Guidelines. The institutional review board at each study site approved the study. All patients enrolled in the study provided written informed consent to participate in the study. Treatment and dose escalation The patients received study treatment for up to 2 years or until disease progression, unacceptable toxicity, or withdrawal of consent. Treatment consisted of an intravenous infusion of cetuximab, followed by an intravenous infusion of FAP-IL2v. Details on drug administration, including prednisone pretreatment, are provided in the Supplementary Methods S1. A starting FAP-IL2v dose of 5 mg was selected from part A, the single-agent dose escalation (7), to dose escalate in combination with cetuximab. A modified continual reassessment method dose escalation with overdose control was used for dose increase. In addition to flat-dosing, intra-patient step-up titration of FAP-IL2v at the second dosing was tested during dose escalation. Dose-limiting toxicity (DLT) criteria are provided in the Supplementary Methods S1. Study population Patients ≥ 18 years were eligible if they had radiologically measurable and clinically evaluable disease; Eastern Cooperative Oncology Group performance score 0 or 1; and life expectancy of ≥12 weeks. Previous standard (including cetuximab) or experimental anticancer treatment was permitted, including radiotherapy, chemotherapy, or immunotherapies (excluding IL2 compounds). A complete list of eligibility criteria and the representativeness of the study population are included in the Supplementary Methods S1 and Supplementary Table S1, respectively. Assessments All adverse events (AE), regardless of relationship to study treatment, were reported according to NCI Common Terminology Criteria for Adverse Event v5.0 and from initiation of study treatment until 3 months after the last dose of study treatment or until the initiation of a post study anticancer treatment, whichever occurred first. Pharmacodynamic assessments were carried out in whole blood samples and fresh or archival tumor biopsies to assess the proposed mechanism of action. Antibodies used for IHC included CD3 (clone 2GV6, Ventana Cat. # 05278422001; RRID: AB_2335978), PRF (clone 5B10, Abcam Cat. # ab89821; RRID: AB_2042606), Ki67 (clone 30-9, Ventana Cat. # 05278384001; RRID: AB_2631262), CD8 (clone SP239, Ventana, Cat. # 09780041001; RRID not available), FOXP3 (clone 236A-E7, Abcam Cat. # ab20034; RRID: AB_445284), FAP (clone SP325, Spring Biosciences aka Abcam Cat. # ab227703; RRID: AB_3106978), KRT (clone AE1/AE3/PCK26, Ventana Cat. # 05267145001; RRID not available), CD16 (SP175; Abcam Cat. # ab183354; RRID: AB_2935850), EGFR (clone 3C6, Ventana Cat. # 790-2988; RRID: AB_2335974), and VENTANA PD-L1 (SP142) assay. For flow cytometry, the Q-TBNK Assay Flow Cytometry Panel was used with the following antibodies from BD Bioscience: CD19 (fluorochrome BV421, clone HIB19, Cat. # 562440, RRID: AB_11153299), CD4 (fluorochrome BV510, clone SK3, Cat. # 659454, RRID: AB_2870492), CD3 (fluorochrome FITC, clone SK7, Cat. # 345764, RRID: AB_2916364), CD16 (fluorochrome PE, clone B73.1, Cat. # 332779, RRID: AB_2868628), CD56 (fluorochrome PE, clone NCAM16.2, Cat. # 345812, RRID: AB_2629216), CD45 (fluorochrome PerCP-Cy5.5, clone 2D1, Cat. # 332784, RRID: AB_2868632), CD8 (fluorochrome APC, clone SK1, Cat. # 345775, RRID: AB_2868803), and CD14 (fluorochrome APC-H7, clone MpH9, Cat. # 641394, RRID: AB_1645725). PK analyses were carried out on serum samples using an ELISA. Validated screening, confirmatory, and titer assays were used to detect antidrug antibodies (ADA) against FAP-IL2v and cetuximab. Tumor response was evaluated according to RECIST v1.1. Details for assessments are provided in the Supplementary Methods S1. Statistical analysis No formal sample size calculation was done for dose-escalation and the expansion part. To further characterize the selected combination regimen, a maximum of 50 response-evaluable patients was planned to be enrolled in the expansion part. The number of checkpoint inhibitor–naïve patients treated was limited to a maximum of 20. The safety analysis included all patients who received at least one dose of study treatment. Patients were evaluable for antitumor activity if they received at least one dose of treatment and had at least one post-baseline tumor assessment or clinical progression before that. Statistical analyses were performed using SAS version 9.4 and R version 3.6.1. PK parameters for FAP-IL2v and cetuximab were determined via noncompartmental analysis. Data availability For up-to-date details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://go.roche.com/data_sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient re-identification. Results Patients Fifty-eight patients were treated at 13 sites in 7 countries between October 9, 2017 and November 10, 2022. Nineteen patients were enrolled in 5 dose-escalation cohorts to receive the treatment combination with the following FAP-IL2v doses: 5 mg FAP-IL2v QW (n = 3), 10 mg QW (n = 1), 10 mg QW/Q2W (n = 7, of whom four were with optional prednisone pretreatment), and 10/15 mg QW/Q2W with optional prednisone pretreatment (n = 8; Supplementary Fig. S1). A dose of 10 mg FAP-IL2v QW/Q2W (the MTD, see safety results below) was further evaluated in the expansion part, which enrolled a further 39 patients, two with optional and 37 with mandatory prednisone pretreatment. The patients had a median age of 61 years at baseline (Table 1). Most had metastatic disease (66%) and had received prior checkpoint inhibitor treatment (79%). Table 1.Patient baseline characteristics.CharacteristicTotal patients (N = 58)Median age (range), years61.0 (39–79)Sex (male/female), n %50 (86)/8 (14)Race, n (%) White35 (60) Asian Indian5 (9) Black or African American2 (3) Unknown16 (28)ECOG, n (%) 011 (19) 147 (81)Primary tumor site, n (%) Oropharynx23 (40) Oral cavity16 (28) Larynx3 (5) Hypopharynx1 (2) Others (including trachea and nasal cavity)10 (17) Unknown5 (9)Disease stage, n (%) Locally advanced20 (34) Metastatic38 (66)Number of prior lines of therapy, n (%) 03 (5) 115 (26) 216 (28) 314 (24) ≥47 (12) NA3 (5)Prior therapy, n (%) CPIa46 (79) Cetuximab34 (58.6) Radiotherapy53 (91.4)Platinum-based chemotherapy Cisplatin19 (31.1) Carboplatin11 (18.0) Oxaliplatin6 (9.8)Abbreviations: ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus; NA, not available; CPI, checkpoint inhibitor.Note: HPV status (or surrogates such as p16 IHC) was not systematically collected in the study and is therefore not reported here.aTreatment with the following compounds was considered prior CPI treatment: budigalimab, cemiplimab, durvalumab, feladilimab, relatlimab, nivolumab, pembrolizumab, durvalumab, ipilimumab, atezolizumab, sotigalimab, and other anti–PD-1 therapy. Patient baseline characteristics. Abbreviations: ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus; NA, not available; CPI, checkpoint inhibitor. Note: HPV status (or surrogates such as p16 IHC) was not systematically collected in the study and is therefore not reported here. Treatment with the following compounds was considered prior CPI treatment: budigalimab, cemiplimab, durvalumab, feladilimab, relatlimab, nivolumab, pembrolizumab, durvalumab, ipilimumab, atezolizumab, sotigalimab, and other anti–PD-1 therapy. The median duration of study treatment was 3.25 months (range: 0–24 months). Fifty-six (97%) patients discontinued study treatment, mostly due to progressive disease (43 patients) or symptomatic deterioration (nine patients; Supplementary Fig. S1). Safety In the dose-escalation part, five patients experienced six DLTs (Supplementary Fig. S1), including grade 4 systemic inflammatory response syndrome and grade 3 events of elevated alanine aminotransferase (two events), elevated aspartate aminotransferase, and thrombocytopenia. Based on these DLTs, the MTD of FAP-IL2v in combination with cetuximab (500 mg/m2, Q2W) was defined to be 10 mg. All 58 patients experienced at least one AE (Supplementary Table S2), and most patients had at least one AE considered related to FAP-IL2v (97%) and at least one AE considered related to cetuximab (90%; Table 2). Expected IL2 class-specific AEs following FAP-IL2v treatment included pyrexia (66%), chills (47%), infusion-related reaction (IRR; 41%), liver function test abnormalities (38%), and edema (21%). The most common FAP-IL2v–related AEs with a grade 3 or 4 severity were hypophosphatemia (19%), lymphopenia (16%), and IRR (14%; Table 2), which had a median duration of 5, 8, and 2 days, respectively. Table 2.Most common (≥10% patients for a study drug) AEs related to FAP-IL2v or cetuximab (N = 58).FAP-IL2v–relatedCetuximab-relatedMedDRA preferred term, n (%)Any gradeGrade 3/4Any gradeGrade 3/4Patients with ≥1 related AE56 (97)34 (59)52 (90)25 (43) Pyrexia37 (64)2 (3)17 (29)1 (2) Chills26 (45)011 (19)0 Fatigue25 (43)2 (3)19 (33)1 (2) Infusion-related reaction24 (41)8 (14)16 (28)6 (10) Nausea21 (36)1 (2)16 (28)1 (2) Aspartate aminotransferase increased16 (28)5 (9)8 (14)2 (3) Alanine aminotransferase increased15 (26)6 (10)7 (12)2 (3) Hypophosphatemia12 (21)11 (19)16 (28)10 (17) Diarrhea11 (19)010 (17)0 Asthenia10 (17)08 (14)0 Hypotension9 (16)1 (2)3 (5)1 (2) Lymphopenia9 (16)9 (16)4 (7)4 (7) γ-Glutamyltransferase increased9 (16)2 (3)3 (5)1 (2) Decreased appetite8 (14)05 (9)0 Blood alkaline phosphatase increased6 (10)02 (3)0 Dermatitis acneiform6 (10)026 (45)0 Dry skin6 (10)010 (17)0 Headache6 (10)06 (10)0 Pruritus6 (10)010 (17)0 Stomatitis6 (10)010 (17)0 Vomiting6 (10)06 (10)0 Skin fissures3 (5)1 (2)10 (17)1 (2) Rash2 (3)08 (14)1 (2) Maculopapular rash5 (9)06 (10)0 Hypomagnesemia3 (5)07 (12)0 Paronychia3 (5)06 (10)2 (3) Most common (≥10% patients for a study drug) AEs related to FAP-IL2v or cetuximab (N = 58). Four patients had an AE leading to discontinuation of FAP-IL2v treatment, one of which was considered related to FAP-IL2v (systemic inflammatory response syndrome, a DLT in a patient in the 10 mg QW dose-escalation cohort). The most common FAP-IL2v–related serious AEs were IRRs (19%), lymphopenia (9%), and pyrexia (3%). Two serious AEs (cardiac arrest and hemorrhage) had a fatal outcome, neither of which was considered related to study treatment. An expected EGFR class-specific AE following cetuximab treatment was dermatitis acneiformis in 26 patients (45%). Other common cetuximab-related AEs included fatigue (33%), pyrexia (29%), and hypophosphatemia, IRR, and nausea (28% each; Table 2). PK/immunogenicity The PK behavior of FAP-IL2v in this study was similar to that after administration as monotherapy; co-administration with cetuximab did not alter the PK behavior of FAP-IL2v. Conversely, the co-administration of the two compounds did not alter the population PK of cetuximab based on data simulated using two different published models for the PK of cetuximab (8, 9). In 39 of 55 (71%) immunogenicity-evaluable patients, ADAs directed against FAP-IL2v were detected in at least one post-dose sample. Sixteen patients had persistent, and 23 patients had transient ADA titers as per the definition provided by Shankar and colleagues (10). None of them showed loss of exposure. Antitumor activity Of the 57 patients who were evaluable for antitumor activity, 4 (7%) patients had partial response as best overall confirmed response (Fig. 1A and B), 27 (47%) patients had stable disease, 22 (39%) had progressive disease, and 4 (7%) had no response assessment but showed clinical progression. The objective response rate (ORR) was 7% [95% confidence interval (CI), 3.2–14.7]. The median progression-free survival was 3.6 months (95% CI, 1.9–4.1). Antitumor activity results based on RECIST 1.1. Best change in target lesions from baseline by CPI status (experienced vs. naïve) in patients (A) with prior cetuximab treatment (n = 32) and (B) without prior cetuximab treatment (n = 20). C, Swimlane plot for response over time by primary tumor type (oropharyngeal vs. non-oropharyngeal tumor) and CPI experience (CPI-experienced vs. -naïve). The number of patients with a primary tumor in the oropharynx was 26, whereas 26 patients had a non-oropharyngeal primary tumor, and for five patients, the primary tumor was unknown. Baseline PD-L1 status determined using Ventana SP142 assay and immune cell/IC or tumor cell/TC staining (PD-L1 negativity defined as IC0 TC0). In the waterfall plots, * denotes patients whose initial response was not confirmed at the subsequent tumor assessment. BOR, best overall response; CPI, checkpoint inhibitor, exp., experienced; Ext, extension; L, local; M, metastatic; NA, not available; NE, not evaluable; N, negative; P, positive; PD, progressive disease; PR, partial response; SD, stable disease; SLD, sum of the longest diameters. Figure 1C depicts the response over time for the 26 patients with oropharyngeal primary tumors and the 26 patients with non-oropharynx primary tumors (for five patients the primary tumor was unknown). In each of the two groups, two patients had a partial response (Supplementary Table S3). A 44-year-old patient whose primary tumor was located in the nasal vestibule and who had received prior anti–PD-1 (cemiplimab) treatment showed a partial response at week 8 and a complete response in all target and nontarget lesions at week 15; however, a new lesion was detected at week 23. Three of the four patients with partial response had locally advanced disease; all four patients had at least two prior lines of systemic treatment. The median duration of response in the four patients was 18.8 months (95% CI, 3.7–NE). Pharmacodynamic/biomarker results Pharmacodynamic changes with focus on QW/Q2W schedule were assessed in peripheral blood for all patients and paired pre- and on-treatment tumor biopsies, which were only available for a subset of patients (n = 14). Consistent with the proposed mode of action, treatment with FAP-IL2v plus cetuximab resulted in pronounced and sustained increases in the absolute counts of NK (9.5-fold induction) and CD8 T cells (3.2-fold induction) in peripheral blood, whereas the effect on CD4 and especially T regulatory cells (Treg) was modest (Fig. 2A). These effects were strongly driven by increased rates of proliferation (Ki67) and were accompanied by systemic immune activation as indicated by increased levels of soluble CD25 and transient elevations in C-reactive protein (Supplementary Fig. S2). In tumor tissue, densities of key immune cell subsets such as T cells, cytotoxic T, and NK cells increased with treatment in a subset of patients. This effect was more pronounced for NK cells [Fig. 2B (upper)]. Overall, there was no clear association with tumor response. Similar observations were made for Tregs and PD-L1 (SP142) expression, whereas EGFR levels showed a mixed pattern [Fig. 2B (lower)]. Pharmacodynamic changes assessed with focus on patients who received a FAP-IL2 dose of 10 mg QW/Q2W. A, Immune cell expansion (NK, CD8+ T cells, CD4+ T cells, and Treg cells) measured in peripheral blood collected at baseline and various post-baseline timepoints. B, Immune cell infiltration density of the tumor microenvironment (CD3+ and CD8+ T cells, proliferating CD8+ T cells, cytotoxic T and NK cells, and Treg cells), PD-L1 expression in immune and tumor cells, and EGFR expression in tumor cells, measured in tumor tissue from biopsies taken at baseline and on-treatment (C2D10). For these exploratory analyses, a greater than 30% reduction in the sum of the longest diameters of the target lesions was considered a response. ABS, absolute count; BL, baseline; C, cycle; D, day, NR, nonresponder; R, responder. The association of baseline biomarker levels (e.g., tumor-infiltrating lymphocyte densities, PD-L1 status, and FAP content) with clinical outcome did not reveal any significant findings, potentially due to the small sample size and limited clinical activity of the tested combination treatment (Supplementary Fig. S3). Of interest, the available tumor samples from responding patients showed a trend toward high EGFR staining, but this was not statistically significant (Supplementary Fig. S3). Human papillomavirus status or surrogates (e.g., p16 IHC) were not systematically captured in this study and are therefore not reported. Discussion This clinical phase Ib study explored the combination of FAP-IL2v with cetuximab in patients with recurrent, unresectable, or metastatic HNSCC, for which there remains a high medical need despite the introduction of the PD-1 inhibitors pembrolizumab and nivolumab (11). For the combination with cetuximab, a FAP-IL2v dose of 10 mg was established as the MTD based on DLTs observed during dose escalation, with QW administration for the first 4 weeks (induction period), followed by a Q2W administration thereafter (maintenance), which allowed synchronization with the approved cetuximab schedule for HNSCC (1 × 400 mg/m2 loading dose, 3 × 250 mg/m2 QW, 500 mg/m2 Q2W). Following the introduction of mandatory pretreatment with corticosteroids in the expansion, the DLTs noted during dose escalation (systemic inflammatory response syndrome, liver enzyme elevations, and thrombocytopenia) were no longer observed. A cetuximab dose of 500 mg/m2 Q2W was explored during dose escalation based on the results from a phase I study showing similar PK and pharmacodynamic data for the Q2W and standard QW cetuximab schedules (400 mg/m2 initial dose, 250 mg/m2 QW; ref. 12). The safety profile of the combination of FAP-IL2v and cetuximab was acceptable and consistent with the known toxicity profile of each individual drug. No unexpected overlapping toxicities were identified. IRRs occur in more than 10% of patients treated with cetuximab overall, with a significantly higher incidence in HNSCC than in patients with colorectal cancer (13). In this study, 41% of patients had IRRs, with 19% having a serious IRR. The frequency of IRR seems to be similar to that in other FAP-IL2v studies (7). The nonrandomized nature of the study makes it difficult to determine whether the combination of cetuximab and FAP-IL2v increased the occurrence of IRRs. AEs consistent with IL2 class-specific effects were manageable. The tolerability of FAP-IL2v seemed to be better than that of aldesleukin, an IL2 analog approved for the treatment of metastatic renal cell carcinoma and metastatic melanoma (14, 15). Aldesleukin is associated with high toxicity, particularly capillary leak syndrome (CLS), which requires close patient monitoring in the hospital (16). In an analysis of 18 studies, the incidence of CLS during IL2 treatment was estimated to be 35% of patients (44% by meta-analysis; ref. 17). In this study, there was no event of CLS following FAP-IL2v treatment, and overall, the relatively low frequency of AEs leading to FAP-IL2v treatment discontinuation (7%) indicates acceptable toxicity. Consistent with the proposed mode of action of IL2 treatment, FAP-IL2v preferentially expanded NK and CD8 T cells in peripheral blood and, only to a lesser extent, CD4 T cells including Tregs. However, this did not translate into a robust increase in tumor-infiltrating lymphocytes. This is in line with the limited number of responses seen in this clinical study with an ORR of 7%. It remains to be elucidated why promising preclinical data on enhancing ADCC (4) did not translate into clinical activity. The high proportion of patients with metastases (66%) may partially explain the limited responses (three of the four patients with a partial response had locally advanced disease). For cetuximab monotherapy, an ORR of 13% (8% in patients with distant metastases) was reported in patients with recurrent and/or metastatic HNSCC who failed to respond to platinum-based therapy (18). Theoretically, the response rate to cetuximab alone may be higher following exposure to anti–PD-1 treatment, due to priming of its immune mechanism. In patients with recurrent and/or metastatic HNSCC previously treated with platinum and anti–PD-1 therapy, the combination of the anti-NKG2A antibody monalizumab and cetuximab achieved an ORR of 20% in a phase II expansion cohort (19). Despite this signal, the follow-on phase III study closed early for futility; the ORR of cetuximab plus placebo was 19% compared with 13% for cetuximab plus monalizumab (20). In patients with recurrent and/or metastatic HNSCC previously treated with cetuximab, platinum, and anti–PD-1 therapy, the combination of the anti-hepatocyte growth factor antibody ficlatuzumab and cetuximab achieved an ORR of 19% and a median progression-free survival of 3.7 months in a phase II study, whereas the ficlatuzumab cetuximab monotherapy arm was closed early for futility (21); there was no cetuximab monotherapy arm. It can be speculated that FAP-IL2v may show greater benefit when combined with cetuximab in the first-line setting. The KEYNOTE-048 trial established the use of pembrolizumab, with or without chemotherapy, as a first-line regimen for metastatic or recurrent HNSCC. The combination of FAP-IL2v and cetuximab may offer benefit particularly to pembrolizumab ineligible and/or PD-L1 low/negative patients, leveraging the augmentation of ADCC as compared with cetuximab alone (22). In conclusion, although the safety profile of FAP-IL2v in combination with cetuximab was acceptable, the overall low antitumor activity does not warrant further clinical exploration of this combination treatment in previously treated HNSCC. At the time of submission of this article, the sponsor had decided to discontinue the development of FAP-IL2v for strategic reasons. Supplementary Material Supplementary Methods. Includes Eligibility criteria for the clinical study, Study Treatment, DLT Criteria, Tumor Response Assessment, and Pharmacodynamic Methods. Supplementary Figure S1. Flow chart. Supplementary Figure S2. Additional pharmacodynamic results. Supplementary Figure S3. Pharmacodynamic changes and associated clinical outcomes. Supplementary Table S1. Representativeness of study participants. Supplementary Table S2. Overview of adverse events. Supplementary Table S3. Characterization of patients with partial response.